Former hedge-fund manager Martin Shkreli became a poster child for greed and sleaze when he bought the only company that was tooled up to make an off-patent drug called Daraprim that people with HIV used to control parasitic toxoplasmosis infections and jacked the price from $13.50 per tablet to $750 per tablet.
Now Imprimis, a young compounding drug company in San Diego has stepped in to make Daraprim at $1/dose. Compounding companies make drugs to order in small batches from substances that are already approved by the FDA, allowing them to make a wide variety of drugs cheaply.
Shkreli is a serial offender, someone who's bought up other drug companies for the express purpose of jacking up off-patent drugs that provide cheap life-prolonging care. Let's hope that Imprimis makes a practice of just following this guy around and destroying his margins until no one will give him any money to invest, ever again.
Imprimis, which primarily makes compounded drugs to treat cataracts and urological conditions, will work with health insurers and prescription benefit managers in each state to make its new capsules and other compounded generic medicines widely available, Baum said.
"We're geared up. We're ready to go as soon as the orders come in," he said.
Compounded drugs are typically made to fill a doctor's prescription for an individual patient, sometimes because the mass-produced version is in short supply or completely unavailable and sometimes to allow for customized formulations or dosages. Compounders don't need Food and Drug Administration approval to do that, unlike drugmakers making huge batches of drugs on complex production lines.
Drug firm offers $1 version of $750 Turing pill
Miles Taylor as chief of staff to DHS undersecretary Kirstjen Nielsen, publicly defending his boss's implementation of the #MuslimBan ethnic cleansing policy and helping to implement the family separation #KidsInCages policy.
At the height of the #MeToo movement, giant management consulting firm Ersnt and Young (AKA "EY") sent a group of women to Power-Presence-Purpose, a "leadership and empowerment" workshop led by Marsha Clark, who advised them that "Women’s brains absorb information like pancakes soak up syrup so it’s hard for them to focus" and "Men’s brains […]
Nest is a home automation company that Google bought in 2014, turned into an independent unit of Alphabet, then re-merged with Google again in 2018 (demonstrating that the "whole independent companies under Alphabet" thing was just a flag of convenience for tax purposes); the company has always focused on "ease of use" over security and […]
Most people don’t spare a lot of thought on the potting for their plants. Perhaps something with a color that matches the walls, but that’s as far as it goes. After all, the plants don’t care what they’re wearing. Do they? Actually, they might. As eye-catching as the AIRSAI Floating Bonsai Plant Pot is, its […]
With the gains real estate has made over stocks in the past 25 years, it’s easy to see why the rich constantly use it to expand their wealth. What’s slightly less obvious is why only the rich seem to ever break into real estate investment. There are a lot of reasons, but a couple of […]
If you’re a coder, there’s a multitude of avenues for you to take your skills. Whether you’re just jumping into the world of programming or looking to rise up the ranks as an established professional, a wide base of knowledge is key. And this Premium 2020 Learn to Code Certification Bundle is a resource that’s […]